Risperdal Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

risperdal

janssen-cilag (new zealand) ltd - risperidone 1 mg/ml (r064766);  ;   - oral solution - 1 mg/ml - active: risperidone 1 mg/ml (r064766)     excipient: benzoic acid purified water sodium hydroxide as 1n solution, to ph 3.0 tartaric acid - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

BACTHECAL baclofen 10 mg/5 mL intrathecal solution for injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/5 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 10 mg/20 mL intrathecal solution for injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/20 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 0.05 mg/1 mL intrathecal solution for injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 0.05 mg/1 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 0.05 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.